Ipragliflozin

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Name
Ipragliflozin
Accession Number
DB11698
Type
Small Molecule
Groups
Investigational
Description

Ipragliflozin is under investigation in Type 2 Diabetes and Diabetes Mellitus, Type 2.

Structure
Thumb
Synonyms
Not Available
Categories
UNII
3N2N8OOR7X
CAS number
761423-87-4
Weight
Average: 404.45
Monoisotopic: 404.109373113
Chemical Formula
C21H21FO5S
InChI Key
AHFWIQIYAXSLBA-RQXATKFSSA-N
InChI
InChI=1S/C21H21FO5S/c22-15-6-5-12(21-20(26)19(25)18(24)16(10-23)27-21)7-13(15)9-14-8-11-3-1-2-4-17(11)28-14/h1-8,16,18-21,23-26H,9-10H2/t16-,18-,19+,20-,21+/m1/s1
IUPAC Name
(2S,3R,4R,5S,6R)-2-{3-[(1-benzothiophen-2-yl)methyl]-4-fluorophenyl}-6-(hydroxymethyl)oxane-3,4,5-triol
SMILES
OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)C1=CC=C(F)C(CC2=CC3=CC=CC=C3S2)=C1

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
2,4-thiazolidinedioneThe risk or severity of hypoglycemia can be increased when Ipragliflozin is combined with 2,4-thiazolidinedione.
5-(2-methylpiperazine-1-sulfonyl)isoquinolineThe therapeutic efficacy of Ipragliflozin can be increased when used in combination with 5-(2-methylpiperazine-1-sulfonyl)isoquinoline.
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypoglycemic activities of Ipragliflozin.
AcarboseThe risk or severity of hypoglycemia can be increased when Acarbose is combined with Ipragliflozin.
AcetazolamideThe therapeutic efficacy of Ipragliflozin can be increased when used in combination with Acetazolamide.
AcetohexamideThe risk or severity of hypoglycemia can be increased when Acetohexamide is combined with Ipragliflozin.
Acetyl sulfisoxazoleThe therapeutic efficacy of Ipragliflozin can be increased when used in combination with Acetyl sulfisoxazole.
Acetylsalicylic acidThe risk or severity of hypoglycemia can be increased when Acetylsalicylic acid is combined with Ipragliflozin.
AgmatineThe risk or severity of hypoglycemia can be increased when Agmatine is combined with Ipragliflozin.
AICA ribonucleotideThe risk or severity of hypoglycemia can be increased when AICA ribonucleotide is combined with Ipragliflozin.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Compound
10453870
PubChem Substance
347828063
ChemSpider
8629286
BindingDB
50381554
ChEBI
134724
ChEMBL
CHEMBL2018096
Wikipedia
Ipragliflozin
ATC Codes
A10BK05 — Ipragliflozin

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedNot AvailableHealthy Volunteers / Pharmacokinetics of ASP19412
1CompletedNot AvailableHealthy Volunteers / Pharmacokinetics of ASP1941 / Pharmacokinetics of Mitiglinide1
1CompletedNot AvailableHealthy Volunteers / Plasma Concentration of ASP19411
1CompletedBasic ScienceBioavailability of Ipragliflozin / Healthy Volunteers1
1CompletedBasic ScienceHealthy Volunteers / Pharmacokinetics of Ipragliflozin1
1CompletedBasic ScienceType 2 Diabetes Mellitus1
2CompletedTreatmentDiabetes Mellitus (DM)1
2CompletedTreatmentType 1 Insulin-Dependent Diabetes Mellitus1
2CompletedTreatmentType 2 Diabetes Mellitus2
3CompletedTreatmentType 1 Insulin-Dependent Diabetes Mellitus1
3CompletedTreatmentType 2 Diabetes Mellitus13
3RecruitingTreatmentType 2 Diabetes Mellitus1
3TerminatedTreatmentType 2 Diabetes Mellitus1
4CompletedOtherType 2 Diabetes Mellitus1
4CompletedTreatmentType 2 Diabetes Mellitus3
4CompletedTreatmentType 2 Diabetes With Non-alcoholic Fatty Liver (NAFLD)1
4TerminatedTreatmentType 2 Diabetes Mellitus1
Not AvailableCompletedNot AvailableType 2 Diabetes Mellitus3

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0299 mg/mLALOGPS
logP2.49ALOGPS
logP2.46ChemAxon
logS-4.1ALOGPS
pKa (Strongest Acidic)12.57ChemAxon
pKa (Strongest Basic)-3ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count4ChemAxon
Polar Surface Area90.15 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity102.41 m3·mol-1ChemAxon
Polarizability40.7 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as phenolic glycosides. These are organic compounds containing a phenolic structure attached to a glycosyl moiety. Some examples of phenolic structures include lignans, and flavonoids. Among the sugar units found in natural glycosides are D-glucose, L-Fructose, and L rhamnose.
Kingdom
Organic compounds
Super Class
Organic oxygen compounds
Class
Organooxygen compounds
Sub Class
Carbohydrates and carbohydrate conjugates
Direct Parent
Phenolic glycosides
Alternative Parents
Hexoses / C-glycosyl compounds / 1-benzothiophenes / 2,3,5-trisubstituted thiophenes / Fluorobenzenes / Oxanes / Aryl fluorides / Heteroaromatic compounds / Secondary alcohols / Polyols
show 5 more
Substituents
Phenolic glycoside / Hexose monosaccharide / C-glycosyl compound / 1-benzothiophene / Benzothiophene / 2,3,5-trisubstituted thiophene / Halobenzene / Fluorobenzene / Aryl fluoride / Monosaccharide
show 18 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available

Drug created on October 20, 2016 14:40 / Updated on June 04, 2019 07:26